Related Experiment Video
Updated: Aug 7, 2026

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
Published on: May 22, 2019
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy
Abstract:
Although gene therapy can cure patients with severe combined immunodeficiency (SCID) syndromes, the clinical occurrence of T cell malignancies due to insertional mutagenesis has raised concerns about the safety of gene therapy. Several key questions have remained unanswered: (i) are there unique risk factors for X-linked SCID (XSCID) gene therapy that increase the risk of insertional mutagenesis; (ii) what other genetic lesions may contribute to transformation; and (iii) what systems can be used to test different vectors for their relative safety? To address these questions, we have developed an XSCID mouse model in which both the Arf tumor-suppressor gene and the gammac gene were ablated. Gene therapy in this animal model recapitulates the high incidence of integration-dependent, T cell tumors that was seen in the clinical trial. Ligation-mediated PCR analysis showed integration sites near or within established protooncogenes (Chd9, Slamf6, Tde1, Camk2b, and Ly6e), demonstrating that T cell transformation was associated with targeting of oncogene loci; however, no integrations within the Lmo2 locus were identified. The X-SCID background in transplanted cells was required for high rate transformation and was associated with expansion of primitive hematopoietic cells that may serve tumor precursors. This model should be useful for testing safety-modified vectors and for further exploring the risk factors leading to insertional mutagenesis in gene therapy trials.
Insights
Gene therapy for severe combined immunodeficiency (SCID) can cause T cell malignancies. A new X-linked SCID (XSCID) mouse model shows gene therapy can lead to tumors by targeting protooncogenes, aiding vector safety testing.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Gene therapy offers cures for SCID but carries risks of T cell malignancies due to insertional mutagenesis.
- Unanswered questions remain regarding specific risk factors, contributing genetic lesions, and vector safety assessment for X-linked SCID (XSCID) gene therapy.
Purpose of the Study:
- To develop and utilize an XSCID mouse model to investigate insertional mutagenesis and T cell transformation in gene therapy.
- To identify unique risk factors and genetic lesions contributing to gene therapy-induced malignancies.
- To establish a system for evaluating the relative safety of different gene therapy vectors.
Main Methods:
- Development of an XSCID mouse model with ablated Arf tumor-suppressor and gammac genes.
- Administration of gene therapy to the animal model to recapitulate clinical observations.
- Ligation-mediated PCR analysis to identify gene integration sites and assess their proximity to protooncogenes.
Main Results:
- The XSCID mouse model demonstrated a high incidence of integration-dependent T cell tumors, mirroring clinical trial outcomes.
- Gene integration sites were frequently found near or within protooncogenes (e.g., Chd9, Slamf6, Tde1, Camk2b, Ly6e), indicating oncogene targeting.
- The X-SCID background was crucial for high transformation rates, linked to the expansion of primitive hematopoietic cells acting as tumor precursors. No integrations within the Lmo2 locus were detected.
Conclusions:
- The developed XSCID mouse model accurately reflects gene therapy-induced T cell malignancies.
- Insertional mutagenesis targeting protooncogenes, particularly within an X-SCID background, is a key mechanism for T cell transformation.
- This model serves as a valuable platform for testing the safety of modified vectors and understanding insertional mutagenesis risks in gene therapy.
Related Concept Videos
In-vitro Mutagenesis
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

